Sana Biotechnology, Inc. (SANA) stock
Close on Nov 17, 2026Market cap $562.80MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $562.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.64
- Dividend yield
- –
- Free cash flow yield
- -24.00%
Fundamentals
- Net income
- -$211.82M
- EPS, diluted
- -$0.76
- Free cash flow
- -$135.06M
- Book value per share
- $0.52
- Diluted shares
- 296M
Trading
- Next earnings
- Mar 2, 2027 (estimated, after the close)
- Previous close
- $1.88
- Open
- $1.88
- Day's range
- $1.84 – $1.92
- Volume
- 2,632,566
- Average volume (20 days)
- 2,709,735
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since May 2021)
- 52-week range
- $1.86 – $5.49
- RSI (14 days)
- 29.8
- Volatility (1 year)
- 76.1%
- Relative volume
- 1.43×
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | SANA | S&P 500 | Difference | SANA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.2% | -4.0% | −13.1 pts | ||
| 3 months | -48.9% | -5.0% | −43.9 pts | ||
| Year to date | -53.8% | +8.2% | −62.1 pts | ||
| 1 year | -48.4% | +11.2% | −59.6 pts | ||
| 3 years | -55.2% | +68.5% | −123.7 pts | -23.5% | +19.0% |
| 5 years | -91.4% | +67.3% | −158.7 pts | -38.8% | +10.8% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sana Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Update
About Sana Biotechnology
Biological Products, (No Diagnostic Substances)
This biotechnology company develops ex vivo and in vivo cell engineering platforms to create therapies for severe medical conditions. Its research focuses on treatments for type 1 diabetes, B-cell malignancies, and autoimmune disorders. The firm's primary product candidates include SC451, an engineered stem cell-derived pancreatic islet cell therapy designed to restore normal glucose levels without immunosuppression, and SG293, an in vivo CAR T therapy delivered via fusosomes to deplete disease-causing B cells. These therapeutic candidates target patients diagnosed with insulin-dependent diabetes, hematologic cancers, and B-cell-driven autoimmune diseases.
Company profile, executives and historySana Biotechnology stock: common questions
What is Sana Biotechnology's stock price?
SANA closed at $1.88 on Nov 17, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.86 and $5.49.
What is Sana Biotechnology's market cap?
Sana Biotechnology was worth $562.80M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is SANA's P/E ratio?
Sana Biotechnology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.76), so it has no meaningful P/E ratio.
Does Sana Biotechnology pay a dividend?
No. Sana Biotechnology has not paid a cash dividend over the last twelve months.
When does Sana Biotechnology report earnings next?
Sana Biotechnology is expected to report Q4 FY2026 results on Mar 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SANA stock performed over the past year?
Including dividends, SANA returned -48.4% over the past year, against +11.2% for the S&P 500.
How many SANA shares are sold short?
41M shares were sold short at the latest FINRA report, 17.63% of the float, or 15.8 days of average trading volume.
Who are Sana Biotechnology's competitors?
Companies most similar to Sana Biotechnology by business, industry and size include IPSC, ALLO, SABS, TCRX, CRBU.
See a number that looks wrong?